Gilead Sciences Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Gilead Sciences Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Foster City
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- GILD
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0000882095
- EIN
- 94-3047598
Board of directors
-
Anthony Welters · DirectorSince 2023
-
Daniel Patrick O'Day · Director · Chairman & CEOSince 2023
-
Harish Manwani · DirectorSince 2023
-
Jacqueline K. Barton · DirectorSince 2023
-
Javier Rodriguez · DirectorSince 2023
-
Jeffrey Bluestone · DirectorSince 2023
-
Kelly A. Kramer · DirectorSince 2023
-
Kevin E. Lofton · DirectorSince 2023
-
Sandra Horning · DirectorSince 2023
-
Ted W. Love · DirectorSince 2024
Chief executives
Daniel Patrick O'Day
· Chairman & CEO
Dates unknown
Director election results
Annual meeting of April 30, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
95.1%
-
96.1%
-
96.3%
-
96.3%
-
97.0%
-
98.0%
-
98.3%
-
98.4%
-
98.6%
Board connections
7 of this board's directors also sit on 15 other boards.
- via Kelly A. Kramer
- via Javier Rodriguez
- via Kelly A. Kramer
- via Ted W. Love
- via Anthony Welters
- via Kevin E. Lofton
- via Kevin E. Lofton
- via Sandra Horning
- via Sandra Horning
- via Sandra Horning
- via Ted W. Love
- via Kelly A. Kramer
- via Ted W. Love
- via Anthony Welters
- via Harish Manwani
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $86,486,820
- 79 sales by 7 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 22, 2026 | Burkhart Erin Officer (SVP, Controllership) | Option exercise | +2,223 | — | — |
| Sep 22, 2026 | Burkhart Erin Officer (SVP, Controllership) | Shares withheld for tax | −768 | $152.67 | $117,251 |
| Sep 15, 2026 | Dickinson Andrew D Officer (Chief Financial Officer) | Open-market sale | −3,000 | $145.29 | $435,870 |
| Sep 15, 2026 | Johanna Mercier Officer (Chief Comm & Corp Aff Officer) | Open-market sale | −1,600 | $143.69 | $229,907 |
| Sep 15, 2026 | Johanna Mercier Officer (Chief Comm & Corp Aff Officer) | Open-market sale | −800 | $144.46 | $115,566 |
| Sep 15, 2026 | Johanna Mercier Officer (Chief Comm & Corp Aff Officer) | Open-market sale | −600 | $145.29 | $87,174 |
| Sep 10, 2026 | Dietmar Berger Officer (Chief Medical Officer) | Option exercise | +533 | — | — |
| Sep 10, 2026 | Cain Wettan Keeley M Officer (EVP Gen Counsel, Legal & Comp) | Option exercise | +590 | — | — |
| Sep 10, 2026 | Dickinson Andrew D Officer (Chief Financial Officer) | Option exercise | +2,797 | — | — |
| Sep 10, 2026 | Daniel Patrick O'Day Director, Officer (Chairman & CEO) | Option exercise | +8,780 | — | — |
| Sep 10, 2026 | Johanna Mercier Officer (Chief Comm & Corp Aff Officer) | Option exercise | +2,797 | — | — |
| Sep 10, 2026 | Dietmar Berger Officer (Chief Medical Officer) | Shares withheld for tax | −263 | $144.81 | $38,085 |
| Sep 10, 2026 | Cain Wettan Keeley M Officer (EVP Gen Counsel, Legal & Comp) | Shares withheld for tax | −285 | $144.81 | $41,271 |
| Sep 10, 2026 | Dickinson Andrew D Officer (Chief Financial Officer) | Shares withheld for tax | −1,347 | $144.81 | $195,059 |
| Sep 10, 2026 | Daniel Patrick O'Day Director, Officer (Chairman & CEO) | Shares withheld for tax | −4,230 | $144.81 | $612,546 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.